Risk factors of intracranial hemorrhage with 125I seeds for the treatment of brain tumors
10.3760/cma.j.cn112138-20210816-00557
- VernacularTitle:颅内肿瘤 125I粒子治疗并发颅内出血危险因素分析
- Author:
Han JIANG
1
;
Shifeng LIU
;
Yan HAN
;
Congxiao WANG
;
Wei ZHANG
;
Wei LI
;
Hao ZHANG
;
Xiaokun HU
Author Information
1. 青岛大学青岛医学院，青岛266000
- Keywords:
Brain neoplasms;
Iodine radioisotopes;
Intracranial hemorrhages;
Risk factors
- From:
Chinese Journal of Internal Medicine
2022;61(3):298-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the risk factors of intracranial hemorrhage after implanting 125-iodine seeds for brain tumors.Methods:A total of 234 patients with intracranial tumors receiving treatment of 125-iodine seeds from March, 2013 to November, 2020 were retrospectively analyzed. Patients were divided into bleeding group and non-bleeding group according to whether postoperative intracranial hemorrhage was reported. Univariate and multivariate analysis was performed by logistic regression to determine the independent risk factors of intracranial hemorrhage.Result:A total of 22 cases (9.4%) reported postoperative intracranial hemorrhage in 234 patients treated with 125-iodine seeds. Univariate analysis showed that the type of tumor and the history of anti-angiogenic drug within one month were possible risk factors ( P<0.1). Multivariate logistic regression analysis showed that anti-angiogenic drug within one month was the independent risk factor for intracranial hemorrhage ( P<0.05). Conclusions:The application of anti-angiogenic drugs within one month is the independent risk factor of intracranial hemorrhage with 125-iodine seeds for the treatment of brain tumors.
